Cytokine Profiling of Erythroderma Biopsies Reveals Types 2 and 17 Immune Activation Status
- 12 December 2024
- journal article
- research article
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 52 (3) , 235-243
Abstract
Background: Erythroderma is a dermatologic condition characterized by widespread red and scaly skin. The causes include, but are not limited to, psoriasis, eczema, drug eruptions, pityriasis rubra pilaris (PRP), and cutaneous T‐cell lymphoma. Most of these are typified by Type 2 (e.g., eczema) or Type 17 (e.g., psoriasis) immune activation. However, since the clinicopathologic features of erythroderma can be nonspecific, assays that determine the underlying immune activation status are desirable.Methods: IL‐13 RNA in situ hybridization and IL‐36 immunohistochemistry were performed on 30 specimens of erythroderma, to ascertain Type 2 and Type 17 immune signatures, respectively.Results: Specimens of erythrodermic psoriasis and PRP showed strong expression of IL‐36 and less than one IL‐13‐positive cell per millimeter. Conversely, those of spongiotic dermatitis showed low expression of IL‐36 and greater than one IL‐13‐positive cell per millimeter. Most specimens of spongiotic, psoriasiform dermatitis demonstrated low IL‐36 expression and greater than one IL‐13‐positive cell per millimeter, but a subset showed high IL‐36 expression and greater than one IL‐13‐positive cell per millimeter.Conclusions: We developed a Type 2/17 immune signature classifier based on cytokine profiling, which showed that cases of erythroderma fall within distinct categories of immune activation. This categorization may have utility in guiding clinical decisions.Keywords
This publication has 30 references indexed in Scilit:
- Clinicopathologic overlap of psoriasis, eczema, and psoriasiform dermatoses: A retrospective study of T helper type 2 and 17 subsets, interleukin 36, and β-defensin 2 in spongiotic psoriasiform dermatitis, sebopsoriasis, and tumor necrosis factor α inhibitor–associated dermatitisJournal of the American Academy of Dermatology, 2020
- Treatment of Pityriasis Rubra Pilaris With GuselkumabJAMA Dermatology, 2019
- Eritrodermia en el adulto: un enfoque práctico para el diagnóstico y tratamientoActas Dermo-Sifiliograficas, 2018
- Biologics for pityriasis rubra pilaris treatment: A review of the literatureJournal of the American Academy of Dermatology, 2018
- IL-36 induces cytokine IL-6 and chemokine CXCL8 expression in human lung tissue cells: Implications for pulmonary inflammatory responsesCytokine, 2017
- Interleukin 23–Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra PilarisJAMA Dermatology, 2017
- Immunologic Overlap of Helper T-Cell Subtypes 17 and 22 in Erythrodermic Psoriasis and Atopic DermatitisJAMA Dermatology, 2015
- Type 2 Helper T-Cell Cytokines Induce Morphologic and Molecular Characteristics of Atopic Dermatitis in Human Skin EquivalentThe American Journal of Pathology, 2011
- Wide-spectrum profile of inflammatory mediators in the plasma and scales of patients with psoriatic diseaseCytokine, 2009
- IL-17 in atopic eczema: Linking allergen-specific adaptive and microbial-triggered innate immune responseJournal of Allergy and Clinical Immunology, 2009